CAL
ORIC icon

Capital Advisors Ltd’s Oric Pharmaceuticals ORIC Stock Holding History

Capital Advisors Ltd’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-166
Closed -$1K – 1522
2022
Q3 		$1K Buy
166
+9
+6% +$36 ﹤0.01% 1082
2022
Q2 		$1K Buy
+157
New +$626 ﹤0.01% 852

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Capital Advisors Ltd's ORIC Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Oric Pharmaceuticals (ORIC) in Q4 2022, closing a stake of 166 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in ORIC in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 65 funds tracked by Wall St. Rank hold ORIC as of Q4 2022.

  • Capital Advisors Ltd reported no remaining Oric Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 166 Oric Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Capital Advisors Ltd first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Capital Advisors Ltd's Oric Pharmaceuticals position peaked at $1K in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.